Casodex (bicalutamid) 150 mg blev undersøgt til behandling af patienter med lokaliseret (T1- T2, N0 eller NX, M0) eller lokalt avanceret (T3- T4, N0, NX, N+, M0; T1- T2, N+, M0) ikke- metasteret prostatacancer i en kombineret analyse af 3 placebokontrollerede studier med i alt 8113 patienter.
CASODEX (Bicalutamide) 150 mg was studied as a treatment for patients with localised (T1-T2, N0 or NX, M0) or locally advanced (T3-T4, any N, M0; T1-T2, N+, M0) non-metastatic prostate cancer in a combined analysis of 3 placebo controlled double-blind studies in 8113 patients, where CASODEX was given as immediate hormonal therapy or as adjuvant to radical prostatectomy or radiotherapy, (primarily external beam radiation).